Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Hemispherx BioPharma, Inc.
Hemispherx BioPharma shares declined 16 percent on nearly 6 million shares traded Tuesday. The company has reported that the FDA has declined to approve its new drug application for Ampligen for Chronic Fatigue Syndrome.
Going forward ... (see research report)
Subscribe to News Feeds